Immune escape pathways from the HBV core(18-27) CD8 T cell response are driven by individual HLA class I alleles

BACKGROUND AND AIMS: There is growing interest in T cell-based immune therapies for a functional cure of chronic HBV infection including check-point inhibition, T cell-targeted vaccines or TCR-grafted effector cells. All these approaches depend on recognition of HLA class I-presented viral peptides....

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Andreas, Schwarz, Tatjana, Brinkmann-Paulukat, Janine, Wisskirchen, Karin, Menne, Christopher, Alizei, Elahe Salimi, Kefalakes, Helenie, Theissen, Martin, Hoffmann, Daniel, Schulze zur Wiesch, Julian, Maini, Mala K., Cornberg, Markus, Kraft, Anke RM, Keitel, Verena, Bock, Hans H., Horn, Peter A., Thimme, Robert, Wedemeyer, Heiner, Heinemann, Falko M., Luedde, Tom, Neumann-Haefelin, Christoph, Protzer, Ulrike, Timm, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686862/
https://www.ncbi.nlm.nih.gov/pubmed/36439181
http://dx.doi.org/10.3389/fimmu.2022.1045498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686862/
https://www.ncbi.nlm.nih.gov/pubmed/36439181
http://dx.doi.org/10.3389/fimmu.2022.1045498

Ejemplares similares